-
Article
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessAuthor Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessCASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG
Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer that expresses myogenic master regulatory factor MYOD but fails to differentiate. Here, we show that the zinc finger transcription factor CASZ1 up-regula...
-
Article
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are an effective treatment for B-cell lymphoma, but often cause neurologic toxicity. We treated 20 patients with B-c...
-
Article
Open AccessAnti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
Chimeric antigen receptor (CAR)-expressing T cells targeting B-cell maturation antigen (BCMA) have activity against multiple myeloma, but improvements in anti-BCMA CARs are needed. We demonstrated recipient an...
